SEC EDGARAUG 111 min read$IRTC

Blackford Quentin S. sold $3.3M of IRTC

Blackford Quentin S. (President and CEO) sold 26,859 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($3.35M total) on 2026-08-10.

Original reporting

SEC EDGAR · Blackford Quentin S.

Published Aug 11, 2026, 8:02 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 11, 2026, 8:08 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$IRTC

Neutral

medium confidence

Mentioned

$IRTC

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$IRTCNeutralLow

Why it matters

Traders may monitor insider activity as a sentiment input, but the disclosure alone does not change the company’s operating outlook.

Market read

A new insider sale of roughly $3.35M was reported, which can slightly influence sentiment but lacks fundamental catalysts in the text.

What to watch

The article notes no 10b5-1 plan, but it still provides no stated reason for the sale, limiting inference about future performance.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IRTCNeutralMedium confidence

Context

IRTC CEO Blackford Quentin S. sold 26,859 shares in an open-market transaction for about $3.35M, per a new Form 4 filing.

Expected impact

Likely limited, short-lived impact unless paired with other negative news.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new guidance, financial results, or a change in business outlook.

Market effects

Sector

Minimal, as this is a routine insider sale with no sector-wide signal in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be driven by diversification or pre-planned liquidity needs, so it may not reflect bearish fundamentals.

Key entities

issuer
iRhythm Holdings, Inc.
Subject of the Form 4 insider sale by its President and CEO.
insider
Blackford Quentin S.
President and CEO who sold 26,859 shares at $124.6514 on 2026-08-10.

Read at source ← All news

SEP 14

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min

SEP 4

$IRTCMed

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

iRhythm Holdings (IRTC) reported Q2 2026 revenues of $224.2M, up 20.1% YoY, and raised full-year guidance to $880-$890M. Gross margin expanded to 72.8%, and adjusted EBITDA grew over 1,000 bps YoY. However, risks include reimbursement uncertainties, execution challenges, and an unresolved FDA warning letter.

tradingview.com3 min

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 16

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

aol.com6 min

AUG 11